# Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

> **NCT00185276** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 365 (actual)

## Conditions studied

- Peripheral Vascular Disease

## Interventions

- **DRUG:** Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- **DRUG:** Gadopentetate dimeglumine (Magnevist, BAY86-4882)

## Key facts

- **NCT ID:** NCT00185276
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185276, "Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00185276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*